GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme.
Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a combination of its antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback